Skip to content

Author

Nita L. Seibel

We have 2 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N)

Abstract Background This is a phase II subprotocol of the National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial evaluating selpercatinib, a RET inhibitor, in children and young adults aged 1-21 years with relapsed or refractory soli...

Andrea T. Franson, Samara L. Potter, P. Williams et al. · 0 citations
Open access Aug 2026

Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay

Comparing AYAs with non-AYAs among patients having relapsed/refractory disease, no significant differences in SNV/indel prevalence were observed, but CCND1 amplifications were more prevalent in AYA breast cancer.

Hari Sankaran, Y. Kotliarov, Ying-Dong Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.